Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936569 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study to Assess the Plaque and Gingivitis Effects of a Stannous Fluoride Dentifrice
A Phase 4 study, sponsored by Procter and Gamble.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT03936569: Completed Phase 4 study, sponsored by Procter and Gamble.
NCT03936569 is a Phase 4 study that has completed, run by Procter and Gamble. The registered enrollment target is 90 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03936569, a Phase 4 study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
The objective of this clinical study is to assess the effects of a 0.454% stannous fluoride dentifrice on gingivitis and plaque after 3 months when compared to a negative control.
Primary Outcome
Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).
Interventions
- DRUG Marketed Toothpaste
- DRUG Marketed Cavity Protection Toothpaste
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2019-01-25 |
| Phase | Phase 4 |
What the finished NCT03936569 record still lists
NCT03936569 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Marketed Toothpaste is the first listed.
NCT03936569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03936569 about?
NCT03936569 is a clinical study titled "A Clinical Study to Assess the Plaque and Gingivitis Effects of a Stannous Fluoride Dentifrice". The objective of this clinical study is to assess the effects of a 0.454% stannous fluoride dentifrice on gingivitis and plaque after 3 months when compared to a negative control.
What is the current status of trial NCT03936569?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2018-10-29. Estimated completion is 2019-01-25.
What interventions are being tested in trial NCT03936569?
The interventions under investigation include: Marketed Toothpaste (DRUG), Marketed Cavity Protection Toothpaste (DRUG).
Who is sponsoring clinical trial NCT03936569?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03936569's enrollment target sits among peer trials
90 886th of 2000 higher than 1,088 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI